23F2G humanized monoclonal antibody: Will begin a Phase I safety trial

Icos Corp. (ICOS), Bothell, Wash. Product: 23F2G humanized monoclonal antibody Indication: Relapsing/remitting multiple sclerosis Status: Will begin a Phase I safety trial within 30 days ...